Augmentin oral suspension is a prescription antibiotic liquid prepared from a powder containing amoxicillin and clavulanate potassium. Standard U.S. formulations are labeled in four concentration pairs: 125 mg/31.25 mg, 200 mg/28.5 mg, 250 mg/62.5 mg and 400 mg/57 mg per 5 mL after reconstitution. Amoxicillin is a penicillin-class antibacterial, while clavulanate inhibits certain beta-lactamase enzymes. The combination is different from plain amoxicillin oral suspension because it contains two active components, and both quantities must be verified when identifying a prescribed liquid product.
The four standard concentrations are not simply different bottle sizes of an identical liquid. The 125/31.25 and 250/62.5 mg per 5 mL suspensions have a 4:1 amoxicillin-to-clavulanic-acid ratio, while the 200/28.5 and 400/57 mg per 5 mL presentations have an approximately 7:1 ratio. These differences matter when interpreting pharmacy labels and evaluating whether a proposed formulation change is appropriate. Standard Augmentin oral suspension must also be distinguished from Augmentin ES-600, a separately labeled pediatric formulation containing 600 mg/42.9 mg per 5 mL with its own indications and substitution restrictions.
For U.S. families, the practical task is to confirm that the dispensed oral suspension matches an existing prescription, including both active ingredients, the complete concentration pair, the bottle's final prepared volume and the pharmacy's preparation instructions. The FDA labeling specifies reconstitution procedures, refrigerated storage after preparation and disposal of unused suspension after 10 days. These product characteristics can help prevent confusion between dry powder, prepared liquid, branded packages and approved generics. A valid prescription and professional pharmacy review remain necessary; this guide does not select pediatric doses, guarantee inventory or recommend changing a prescribed formulation.
Standard Augmentin oral suspension is a liquid dosage form of the fixed combination of amoxicillin and clavulanate potassium. The product is supplied as a powder that is mixed with a specified quantity of water before dispensing. After preparation, the liquid contains both active components at the concentration stated on the product label. The preparation process matters because the strength is expressed per volume of the finished suspension rather than per dry-powder package.
Amoxicillin interferes with bacterial cell-wall synthesis in susceptible organisms. Clavulanate inhibits certain beta-lactamase enzymes capable of inactivating amoxicillin. The combination can therefore retain activity against some bacteria for which plain amoxicillin may be insufficient. It does not overcome all resistance mechanisms and should not be considered a universally preferable antibiotic.
The term Augmentin liquid is sometimes used broadly in prescription searches, but it can refer to different products. Standard immediate-release suspensions have four FDA-labeled concentration pairs, while Augmentin ES-600 is a separate formulation. The established ingredient name amoxicillin and clavulanate potassium may also appear on generic product labels without the Augmentin proprietary name.
Liquid Augmentin is particularly relevant when the prescribed patient cannot swallow conventional tablets or when a pediatric formulation is appropriate. Nevertheless, the choice of concentration and administration instructions depends on the clinical indication, age, weight and other medical considerations. An oral liquid is not automatically suitable for every patient simply because it is easier to administer than a tablet.
The broader Augmentin brand guide identifies the complete branded family, while the generic amoxicillin/clavulanate guide explains the relationship between branded and generic two-ingredient products. This page concentrates on standard oral suspensions and their pharmacy identification requirements.
The July 2026 FDA prescribing information identifies four standard Augmentin oral suspension concentrations. Each strength is expressed as the quantity of amoxicillin followed by the quantity of clavulanic acid in 5 mL of the prepared liquid. The clavulanic-acid amount is supplied as clavulanate potassium. Both components are part of the labeled concentration and must remain visible when comparing products.
The 125 mg/31.25 mg and 250 mg/62.5 mg per 5 mL suspensions have a 4:1 component ratio. The 200 mg/28.5 mg and 400 mg/57 mg per 5 mL suspensions have approximately 7:1 ratios. These differences are relevant to formulation identity and FDA substitution guidance. A product cannot be considered equivalent to another merely because its amoxicillin concentration appears familiar.
A concentration such as 400 mg/57 mg per 5 mL does not mean that the entire bottle contains only those quantities. It means that every correctly prepared and measured 5 mL portion contains the stated amounts. The final bottle volume is a separate package characteristic, and the actual amount administered must follow the prescription rather than assumptions based on the labeled concentration.
The four concentrations belong together on this page because they represent one standard oral-suspension product family. Creating a separate informational page for each concentration would duplicate much of the same identification, preparation and pharmacy-verification information without necessarily serving a distinct user need.
These strengths are regulatory product descriptions rather than recommendations for pediatric treatment. A clinician determines the appropriate medicine and regimen, and the dispensing pharmacist ensures that the supplied concentration and label correspond to the prescription.
| FDA-labeled concentration | Amoxicillin per 5 mL | Clavulanic acid per 5 mL | Component ratio | Product distinction |
|---|---|---|---|---|
| 125 mg/31.25 mg per 5 mL | 125 mg | 31.25 mg | 4:1 | Standard suspension concentration with a 4:1 ingredient proportion. |
| 200 mg/28.5 mg per 5 mL | 200 mg | 28.5 mg | Approximately 7:1 | Standard suspension concentration with a different ingredient proportion from the 125/31.25 family. |
| 250 mg/62.5 mg per 5 mL | 250 mg | 62.5 mg | 4:1 | Standard suspension with twice the concentration of each component in the 125/31.25 presentation. |
| 400 mg/57 mg per 5 mL | 400 mg | 57 mg | Approximately 7:1 | Standard suspension with twice the concentration of each component in the 200/28.5 presentation. |
A two-component concentration describes more than the amount of amoxicillin in a liquid medicine. The clavulanic-acid quantity also contributes to the pharmaceutical identity. Standard Augmentin suspensions are grouped into two principal component-ratio families, reflecting different proportions of amoxicillin and clavulanate in their finished formulations.
The 125 mg/31.25 mg and 250 mg/62.5 mg concentrations both have a 4:1 ratio. The higher concentration contains twice the quantity of each active component per 5 mL. However, this arithmetic relationship does not authorize a caregiver to halve or double a measured volume when a pharmacy supplies a different concentration. The prescribed directions and actual dispensed label must govern administration.
The 200 mg/28.5 mg and 400 mg/57 mg concentrations share an approximately 7:1 ratio. Their relationship is similar in that the higher concentration contains twice the active-component amounts per 5 mL. The approximately 7:1 family nevertheless differs from the 4:1 family in its clavulanate proportion relative to amoxicillin.
These ratios help explain why two products described simply as Augmentin suspension cannot automatically be exchanged. A change in concentration may affect the required measured volume, while a change in ratio may affect exposure to clavulanate relative to amoxicillin. The FDA provides formulation-switching restrictions, but those restrictions are intended for professional medication management rather than self-directed conversions.
The correct interpretation of a prescription therefore requires the complete concentration pair and the final dosage form. A pharmacist can clarify whether a particular approved product matches the prescription or whether a prescriber must evaluate a proposed change. The ratio is an identification tool, not a measure of which suspension is stronger or clinically better.
An Augmentin oral suspension bottle has two different volume-related characteristics: the intended final volume after reconstitution and the quantity of water used to prepare it. These values should not be confused. The FDA provides specific package-dependent water quantities because the powder occupies volume and the final prepared suspension is not obtained by adding a volume of water equal to the labeled final bottle size.
In the July 2026 FDA prescribing information, Table 5 lists 75 mL, 100 mL and 150 mL final bottle sizes for the standard 125/31.25 and 250/62.5 mg per 5 mL suspensions. The 200/28.5 and 400/57 mg per 5 mL suspensions have listed final bottle sizes of 50 mL, 75 mL and 100 mL. These are FDA-labeled presentations, not promises about which original branded packages are currently stocked.
The same nominal concentration can therefore appear in multiple package sizes. A pharmacy quote or dispensing record must identify the actual product and prepared quantity rather than relying only on the concentration. A product listing displaying 400 mg/57 mg per 5 mL does not establish whether a 50 mL, 75 mL or 100 mL package will be supplied.
For generic products, approved package configurations and labeler information must be checked against the specific generic labeling. A branded package described in FDA prescribing information should not automatically be assigned to every generic manufacturer or repackager.
Parents and caregivers should rely on the dispensing pharmacy to prepare the medicine and confirm the final volume, concentration and labeled directions. The preparation values shown below are regulatory product records for verification, not instructions to mix a prescribed medicine independently.
| FDA-labeled suspension | Final bottle sizes | Corresponding water quantities | Important interpretation |
|---|---|---|---|
| 125 mg/31.25 mg per 5 mL | 75 mL; 100 mL; 150 mL | 67 mL; 90 mL; 134 mL | Water quantities correspond to the listed final bottle sizes in the same order. |
| 200 mg/28.5 mg per 5 mL | 50 mL; 75 mL; 100 mL | 50 mL; 75 mL; 95 mL | Reconstitution quantities are package-specific. |
| 250 mg/62.5 mg per 5 mL | 75 mL; 100 mL; 150 mL | 65 mL; 87 mL; 130 mL | The prepared volume differs from the quantity of water added. |
| 400 mg/57 mg per 5 mL | 50 mL; 75 mL; 100 mL | 50 mL; 70 mL; 90 mL | Preparation must follow the specific approved product instructions. |
Standard Augmentin oral suspension is generally supplied as a dry powder rather than as a finished liquid ready for immediate administration. Reconstitution means adding a specified amount of water to the powder to create the final oral suspension. The July 2026 FDA labeling directs preparation at the time of dispensing and provides a defined procedure for the relevant formulation and bottle size.
Under the FDA procedure, the dry powder is loosened before the measured water is added in two portions, with vigorous shaking after each addition. This two-stage process is designed to produce an appropriately mixed suspension. The necessary water volume depends on the concentration and bottle size, so the preparation instructions cannot be generalized from one package to another.
Reconstitution should be handled according to the specific product's approved labeling and the dispensing pharmacy's procedures. Patients and caregivers should not guess the amount of water required for a bottle or assume that directions found for another concentration or manufacturer apply to their product.
Once prepared, the pharmacy should provide a container label identifying the medicine, concentration, prescribed administration instructions and relevant storage or discard information. If a patient receives what appears to be unprepared powder when a ready-to-administer suspension was expected, the preparation status should be clarified with the pharmacist before any dose is given.
The labeled final concentration applies after correct preparation. Adding an incorrect quantity of water can change the concentration of both active ingredients and make the prescribed measured volume inaccurate. This is why product identity, preparation status and the pharmacy dispensing record are integral to safe liquid-medication verification.
Reconstitution is separate from ordinary shaking before administration. Even after the suspension has been correctly prepared, the FDA directs users to shake the container well before each use. Families should follow the actual dispensed product's instructions rather than relying on a generic preparation example.
The FDA distinguishes storage requirements for unreconstituted Augmentin powder from those for the finished liquid. The July 2026 labeling specifies storage of unreconstituted powder at or below 25°C (77°F). After preparation, the suspension must be kept in its original container under refrigeration. The change in storage requirements is an important part of pharmacy dispensing and caregiver instructions.
The FDA directs that unused reconstituted Augmentin oral suspension be discarded after 10 days. This is a preparation-related stability limit, not a recommendation for the duration of antibiotic treatment. A prescribed course may have a different duration, which must be determined by the healthcare professional. The patient should follow the prescription and the pharmacy's prepared-on and discard-date instructions.
A slight color change during storage is described as normal in the FDA prescribing information. However, the statement does not mean that every appearance change is acceptable or that the suspension remains usable after improper storage. Questions about an unusual appearance, contamination, missed refrigeration or an uncertain preparation date should be directed to the dispensing pharmacist.
The FDA also instructs users to shake the suspension well before each administration. This requirement reflects the nature of a suspension, in which the medication must be adequately dispersed before measuring the prescribed amount. The measuring device should be appropriate for oral medication, and its use should be explained by the pharmacist.
Families should not save unused reconstituted antibiotics for a later illness. The product has a defined post-reconstitution discard period, and a new illness requires an appropriate clinical assessment. Unused medicine should be discarded according to pharmacy instructions rather than kept beyond the labeled limit.
Storage and handling can also be relevant when a prescription is filled through a pharmacy offering delivery. The Augmentin prescription delivery guide discusses dispensing and transport considerations without implying that shipping is available or appropriate for every liquid product.
| Handling stage | FDA-labeled requirement | Practical verification |
|---|---|---|
| Unreconstituted powder | Store at or below 25°C (77°F). | Confirm the product is still dry powder and follow its specific package labeling. |
| Preparation | Reconstitute according to the labeled water quantity for the bottle size. | Confirm the pharmacy prepared the intended concentration. |
| Prepared suspension | Store in the original container under refrigeration. | Check the dispensing label for refrigeration instructions. |
| Before each use | Shake well. | Follow pharmacy instructions for using the prescribed measuring device. |
| Post-reconstitution stability | Discard unused suspension after 10 days. | Use the pharmacy's preparation and discard-date information. |
| Appearance during storage | A slight color change may be normal. | Ask the pharmacist about unexpected changes or storage concerns. |
Oral suspensions are particularly relevant in pediatric care because some children cannot swallow conventional tablets and because liquid concentrations permit a prescribed volume to be administered using an appropriate measuring device. The FDA's July 2026 labeling identifies standard Augmentin oral suspension for pediatric patients weighing less than 40 kg and for adults or pediatric patients who cannot swallow tablets, within the applicable labeled indications.
The presence of several liquid concentrations does not create a universal pediatric strength recommendation. The appropriate formulation and regimen depend on the diagnosis, age, weight, relevant clinical factors and prescribed instructions. A caregiver cannot determine the correct product merely by selecting the highest or lowest amoxicillin concentration shown in a pharmacy catalog.
Children younger than 3 months and older pediatric patients have distinct dosing considerations in the FDA labeling. These clinical distinctions are important, but this product-identification page does not convert them into patient-specific dosing charts. The prescribed concentration and administration directions must come from a qualified healthcare professional.
Liquid formulations also require attention to measurement. The FDA labeling recommends an appropriate dosing spoon or medicine dropper for pediatric administration and directs that the device be rinsed after use. A pharmacist may supply an appropriate oral dosing device and explain how to measure the prescribed amount accurately. Household kitchen spoons should not be assumed to provide accurate medicinal measurements.
Parents and caregivers should verify both the concentration and the prescribed measured volume. If a refill or another pharmacy supplies a different concentration, the original volume instructions should not be assumed to remain valid. The pharmacist or prescriber must assess the change and provide correct labeling before administration.
Standard Augmentin oral suspensions should also be distinguished from Augmentin ES-600, which has separate pediatric indications, concentration and substitution restrictions. The fact that both are liquids does not make them freely interchangeable.
Augmentin ES-600 is a separately identified oral suspension within the broader branded amoxicillin/clavulanate family. The July 2026 FDA labeling lists ES-600 at 600 mg of amoxicillin and 42.9 mg of clavulanic acid per 5 mL after reconstitution. Its ingredient proportion differs from the 4:1 and approximately 7:1 families of standard Augmentin oral suspensions.
ES-600 has a distinct labeled pediatric population and specific indications that include acute bacterial sinusitis and recurrent or persistent acute otitis media under the FDA's stated conditions. Those indication and population requirements should not be generalized to every standard Augmentin suspension.
The FDA expressly states that Augmentin ES-600 is not substitutable with other Augmentin or Augmentin XR formulations. It should not be used as a replacement for conventional 500 mg/125 mg or 875 mg/125 mg tablets. This restriction exists even though ES-600 shares the same two active ingredients as other products in the family.
A pharmacy catalog may group all of these products under amoxicillin/clavulanate oral suspension, but the separate strengths, component ratios, labeled populations and regulatory product identities must remain clear. The phrase Augmentin liquid is insufficient to establish that a displayed ES-600 product matches a prescription for a standard suspension.
The dedicated Augmentin ES-600 product guide covers that separate formulation in detail. This page intentionally limits its main product comparison to the four standard immediate-release suspension concentrations.
| Product family | Labeled concentrations | Component ratios | Key distinction |
|---|---|---|---|
| Standard Augmentin oral suspension | 125/31.25; 200/28.5; 250/62.5; 400/57 mg per 5 mL | 4:1 or approximately 7:1 | Four standard oral-suspension concentrations with formulation-specific prescribing and substitution requirements. |
| Augmentin ES-600 oral suspension | 600/42.9 mg per 5 mL | Approximately 14:1 | Separately labeled pediatric formulation; not substitutable with standard Augmentin or XR. |
Standard Augmentin oral suspensions share the same active ingredients as conventional Augmentin tablets and chewable tablets, but their dosage forms and component ratios can differ. A liquid concentration expressed per 5 mL should not be interpreted as equivalent to a tablet containing a numerically similar amoxicillin amount.
For example, the conventional 250 mg/125 mg tablet contains 125 mg of clavulanic acid, while 5 mL of the 250 mg/62.5 mg suspension contains only 62.5 mg. The FDA identifies no equivalent suspension or chewable strength for the conventional 250/125 mg tablet in its formulation-switching guidance. The 250 mg amoxicillin figure alone is therefore insufficient to establish interchangeability.
The FDA also identifies certain professionally managed formulation-switching relationships for the conventional 500 mg/125 mg and 875 mg/125 mg tablets. Those relationships depend on matching component ratios and the specific permitted formulation families, with additional patient-population restrictions. They are not one-unit-for-one-unit conversion instructions or authorization for caregivers to change a prescription independently.
The standard Augmentin chewable tablets include the same labeled strength pairs as the four standard oral suspensions when expressed per chewable tablet rather than per 5 mL of prepared liquid. The FDA permits certain chewable-to-suspension substitutions on a milligram-for-milligram basis when appropriate, but the relevant formulation and patient conditions must still be satisfied.
For a broader tablet comparison, see the Augmentin immediate-release tablets guide. The Augmentin chewable tablets guide addresses chewable product identity, while the Augmentin 250/125 mg tablet guide explains the especially important distinction from 250/62.5 mg liquid and chewable products.
Augmentin is a proprietary brand name, while amoxicillin and clavulanate potassium is the established ingredient name used for generic combination products. FDA-approved generic oral suspensions may correspond to appropriate reference products, but their regulatory status must be confirmed for the specific dosage form and concentration. A generic product should not be assumed equivalent to every liquid formulation merely because the active ingredients are the same.
Generic products approved through an Abbreviated New Drug Application, or ANDA, must meet applicable FDA requirements. The Orange Book can help identify approved products and relevant therapeutic-equivalence evaluations, while published product labeling can identify the concentration, labeler, NDC and package characteristics. These resources serve different verification purposes and do not replace pharmacy confirmation.
A generic liquid may differ from the branded product in flavor, appearance, inactive ingredients, labeler or package design within applicable regulatory requirements. Such differences may be legitimate, but the actual supplied product must still match the prescription and applicable approval and dispensing conditions.
Manufacturers and labelers may offer different approved package configurations. A concentration appearing in the FDA's brand label does not establish that every generic manufacturer offers the same bottle size. The pharmacy must confirm the actual product, concentration and dispensed quantity rather than relying on a broad generic search result.
Authorized generics are also distinct from independently approved ANDA products. A product marketed without the brand name under an approved brand NDA has a different regulatory relationship from a separately approved ANDA generic. The actual application and labeling records, not the word generic alone, establish that distinction.
Readers seeking the wider FDA approval context can consult the FDA-approved Augmentin products guide, while the generic amoxicillin/clavulanate manufacturers directory addresses applicant, manufacturer and labeler identities. This page does not attempt to maintain a complete list of current liquid manufacturers.
A legitimate U.S. pharmacy must dispense Augmentin oral suspension under a valid prescription and applicable pharmacy requirements. Verification begins with the prescribed medicine and the complete two-component concentration. The pharmacy should confirm whether the product is standard Augmentin oral suspension or a different formulation such as ES-600.
The dispensing label should identify the active ingredients, strength expressed per 5 mL, actual product name, prescribed administration directions and relevant preparation or storage details. A concentration written only as amoxicillin 400 mg/5 mL does not fully identify the combination product because it omits the clavulanate quantity.
The pharmacy should also reconcile the prepared final volume, manufacturer or labeler and package identifier where applicable. An NDC may help identify a particular listed package, but it does not independently establish FDA approval, authenticity, current supply or clinical appropriateness.
Families should confirm whether the bottle has already been reconstituted and which storage and discard instructions apply. They should also understand how to shake the suspension and use the supplied measuring device according to the pharmacy's directions. If a different concentration is dispensed from one previously used, administration instructions must be reviewed rather than carried over automatically.
A pharmacy website may display historic products, multiple generic manufacturers or package sizes that are not actually stocked. Approval and published labeling are not real-time inventory records. The licensed dispensing pharmacy must confirm the product it can supply, and any substitution must comply with the prescription and applicable requirements.
For general prescription-based purchasing questions, see the U.S. Augmentin buying guide. The Augmentin online pharmacy guide covers pharmacy-verification requirements. This suspension page remains focused on identifying the correct liquid and its handling instructions.
| Verification item | What to confirm | Why it matters |
|---|---|---|
| Prescription | Valid prescription specifying the intended combination medicine | Augmentin is not an over-the-counter antibiotic. |
| Concentration | Both amoxicillin and clavulanic acid quantities per 5 mL | Prevents confusion between the four standard suspensions. |
| Formulation | Standard suspension or separately labeled ES-600 | Different products are not freely interchangeable. |
| Preparation status | Dry powder or properly reconstituted suspension | The labeled liquid concentration applies after correct preparation. |
| Final volume | Bottle size or actual prepared dispensing quantity | Distinguishes concentration from total package quantity. |
| Manufacturer and NDC | Actual supplied product and package identifiers where applicable | Helps reconcile the dispensed medicine with official labeling. |
| Storage and discard date | Refrigeration and 10-day post-reconstitution limit | Supports correct handling of the prepared suspension. |
| Administration device | Appropriate calibrated oral measurement device and pharmacy instructions | Reduces the risk of inaccurate liquid measurement. |
Standard Augmentin oral suspensions contain amoxicillin, a penicillin-class antibacterial, together with clavulanate potassium. The FDA labeling identifies serious hypersensitivity reactions to Augmentin or other beta-lactam antibacterial drugs and previous Augmentin-associated cholestatic jaundice or hepatic dysfunction among the contraindications. These considerations apply regardless of whether the liquid is branded or appropriately approved as a generic.
Common adverse reactions associated with amoxicillin/clavulanate can include diarrhea, nausea, vomiting and skin reactions. Serious risks include anaphylaxis, severe skin reactions, liver injury, drug-induced enterocolitis syndrome and Clostridioides difficile-associated diarrhea. Sudden breathing difficulty or facial or throat swelling requires emergency medical attention. Other concerning symptoms should be assessed promptly by a healthcare professional.
The complete medication and allergy history matters when a liquid antibiotic is prescribed. The FDA prescribing information discusses interactions or precautions involving drugs such as probenecid, oral anticoagulants and allopurinol. Kidney function and other clinical circumstances may also influence professional prescribing and monitoring decisions.
The existence of different liquid concentrations does not authorize caregivers to select a concentration or estimate a treatment volume independently. An error involving a two-component concentration can change exposure to amoxicillin, clavulanate or both. The prescription and pharmacy label should govern administration, and discrepancies should be resolved before the medicine is given.
Antibiotics should be used only when clinically appropriate for susceptible bacterial infections. Augmentin does not treat influenza, the common cold or other viral illnesses. Families should not reuse leftover suspension, save a partially used bottle for another illness or share prescription medicines.
For additional information about hypersensitivity to penicillin-class medicines, see the penicillin allergy guide. This page does not provide personalized pediatric treatment advice or replace consultation with a prescriber or pharmacist.
The actual cost of Augmentin oral suspension depends on the prescribed concentration, final volume, brand or generic product, pharmacy and applicable insurance or discount arrangements. A price listing for one concentration or bottle size should not automatically be treated as a quotation for another liquid presentation.
The difference between concentration and prepared volume is especially important when comparing offers. A 400 mg/57 mg per 5 mL bottle prepared to a final volume of 50 mL is not the same package quantity as a 100 mL bottle of the same concentration. The labeled concentration may match while the supplied total volume differs.
Brand and generic products may have different package identifiers, labelers, pricing and distribution arrangements. FDA approval and published product labels do not guarantee that a particular package is currently stocked by a pharmacy. A pharmacy must confirm actual availability for the existing prescription.
Delivery and pickup introduce additional handling questions because the medicine may be supplied as dry powder or as a reconstituted liquid requiring refrigeration. Patients should confirm the preparation status, storage instructions and dispensing arrangements with the pharmacy. A general online delivery advertisement does not establish that every liquid Augmentin product can be transported or dispensed under the same conditions.
The Augmentin suspension price guide addresses concentration-specific and bottle-size cost comparisons. Broader brand pricing belongs in the Augmentin price guide. This page intentionally avoids unsourced retail prices, guaranteed inventory, assumed insurance coverage or delivery promises.
The central buyer task is to verify the exact approved product and the quantity to be dispensed before interpreting any price or availability claim. A valid prescription, correct concentration and appropriate preparation remain more important than a broad product-search match.
Augmentin oral suspension is a prescription liquid antibiotic prepared from a powder containing amoxicillin and clavulanate potassium. Standard formulations contain both active components in labeled quantities per 5 mL after reconstitution. It is different from plain amoxicillin suspension.
The July 2026 FDA labeling identifies four standard oral suspension strengths: 125 mg/31.25 mg, 200 mg/28.5 mg, 250 mg/62.5 mg and 400 mg/57 mg per 5 mL. Each pair identifies amoxicillin followed by clavulanic acid.
It means that 5 mL of properly prepared suspension contains 400 mg of amoxicillin and 57 mg of clavulanic acid, supplied as clavulanate potassium. The numbers describe the concentration of the prepared liquid, not the total amount in the bottle.
No. Plain amoxicillin oral suspension contains amoxicillin without clavulanate. Augmentin suspension contains both amoxicillin and clavulanate potassium. They are different prescription medicines and should not be exchanged without professional assessment.
Both standard suspensions have a 4:1 amoxicillin-to-clavulanic-acid ratio. The 250/62.5 mg per 5 mL product contains twice the concentration of each active ingredient. A change in concentration requires professional review and correct prescription instructions rather than independent changes to the measured volume.
Both standard suspensions have approximately 7:1 ingredient ratios. The 400/57 mg per 5 mL formulation contains twice the amount of each active component per 5 mL compared with the 200/28.5 mg product. They should not be exchanged without appropriate pharmacy or prescriber review.
Not automatically. Standard suspensions have different concentrations and two principal ingredient-ratio families. The FDA recognizes certain formulation substitutions under specified conditions, but these do not authorize caregivers to change concentrations, measured volumes or prescribed regimens independently.
Yes. Standard Augmentin oral suspension is supplied as powder for reconstitution. The appropriate quantity of water is added according to the specific product's approved instructions, typically during pharmacy dispensing, to prepare the finished liquid concentration.
Reconstitution must follow the exact instructions for the product, strength and bottle size. The FDA specifies preparation at the time of dispensing. Patients should have the dispensing pharmacy confirm whether the bottle has been correctly prepared and should not guess the required quantity of water.
The July 2026 FDA labeling lists 75 mL, 100 mL and 150 mL final bottle sizes for the 125/31.25 and 250/62.5 mg per 5 mL suspensions. The 200/28.5 and 400/57 mg per 5 mL suspensions have listed sizes of 50 mL, 75 mL and 100 mL. Current pharmacy availability must be checked separately.
Yes. The July 2026 FDA prescribing information directs that reconstituted Augmentin oral suspension be stored in its original container under refrigeration. Families should follow the specific dispensed product's storage label and ask the pharmacist about any interruption in refrigeration.
The FDA labeling directs that unused reconstituted suspension be discarded after 10 days. This is a storage-stability period after preparation, not a recommendation for treatment duration. Patients should follow the prescribed course and the pharmacy's preparation and discard-date instructions.
Yes. FDA labeling instructs users to shake the reconstituted suspension well before each use. The prescribed amount should be measured with an appropriate oral medication device according to pharmacy instructions.
The FDA labeling states that a slight color change during refrigerated storage can be normal. However, unusual appearance, suspected contamination or improper storage should be discussed with the pharmacist before using the medicine.
No. Augmentin ES-600 is a distinct pediatric oral suspension containing 600 mg of amoxicillin and 42.9 mg of clavulanic acid per 5 mL. It has different labeled indications and ingredient proportions. The FDA states that ES-600 is not substitutable with other Augmentin or XR formulations.
No direct equivalence exists. The suspension contains 62.5 mg of clavulanic acid per 5 mL, while the conventional 250/125 mg tablet contains 125 mg per tablet. The FDA identifies no equivalent suspension strength for that conventional tablet in its formulation-switching table.
The FDA identifies certain formulation-switching relationships between specified conventional tablets and oral suspensions. Those relationships depend on the applicable component ratios, formulations and patient circumstances. They do not authorize patients or caregivers to calculate substitute volumes independently.
The July 2026 FDA labeling includes standard Augmentin oral suspension for adults and pediatric patients who cannot swallow conventional tablets, within the relevant labeled indications. A clinician must determine whether the formulation and prescribed regimen are appropriate.
No. Standard Augmentin oral suspension is particularly relevant in pediatric care, but FDA labeling also addresses its use in adults who cannot swallow tablets. The suitable dosage form and regimen depend on a professional clinical assessment.
An appropriately FDA-approved generic may be therapeutically equivalent to its corresponding reference product when the applicable requirements are met. The specific dosage form, complete concentration pair, approval relationship and substitution requirements must be verified. Generic flavors, labels and package appearances may differ.
Check the pharmacy label for both active ingredients, the complete concentration per 5 mL, the prescribed directions and the preparation and discard information. Ask the pharmacist to confirm the actual brand or generic product, final volume, manufacturer or labeler and NDC where applicable.
No. Augmentin oral suspension is a prescription-only antibiotic in the United States. Legitimate dispensing requires a valid prescription and compliance with applicable pharmacy requirements. An online listing does not establish prescription-free access or guaranteed approval.
No. FDA approval and published labeling establish product and regulatory information, not current inventory. A pharmacy must confirm whether the specific branded or generic concentration and package can actually be dispensed.
No. Reconstituted Augmentin suspension has a limited storage period and should not be saved for later self-treatment. A new illness requires appropriate clinical evaluation, and leftover antibiotics may be unsuitable or unnecessary.
Augmentin contains amoxicillin, a penicillin-class antibacterial. FDA labeling contraindicates use in patients with a history of serious hypersensitivity reactions to Augmentin or other beta-lactam antibacterial drugs. A reported allergy should be evaluated by a healthcare professional before prescribing.